Homepage > Company > Media > Pharma News > 2022 > Axsome Therapeutics to Acquire Jazz Pharmaceuticals’ Sleep-Combating Drug Sunosi

Axsome Therapeutics to Acquire Jazz Pharmaceuticals’ Sleep-Combating Drug Sunosi

Jazz Pharmaceuticals agreed to divest its Sunosi (solriamfetol) drug to Axsome Therapeutics that includes an upfront payment of $53 million.

Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor that has FDA and EU approval for treatment of excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea.

Jazz earned $57.9 million from Sunosi sales in 2021, an increase of 104 percent from the previous year.

Solriamfetol, sold under the brand name Sunosi, is a medication used for the treatment of excessive sleepiness associated with narcolepsy and sleep apnea. It is derived from d-phenylalanine and its chemical name is (R)-2-amino-3-phenylpropylcarbamate hydrochloride. It is a norepinephrine–dopamine reuptake inhibitor (NDRI). Common side effects include headache, nausea, anxiety, and trouble sleeping.The drug was discovered by a subsidiary of SK Group, which licensed rights outside of eleven countries in Asia to Aerial Pharma in 2011.

March 29, 2022

https://www.fdanews.com/

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...